- Home
- PPBI vs IBRX Comparison
PPBI vs IBRX Comparison
Compare PPBI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- IBRX
- Stock Information
- Founded
- PPBI 1983
- IBRX 2014
- Country
- PPBI United States
- IBRX United States
- Employees
- PPBI N/A
- IBRX N/A
- Industry
- PPBI Major Banks
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBI Finance
- IBRX Health Care
- Exchange
- PPBI Nasdaq
- IBRX Nasdaq
- Market Cap
- PPBI 2.7B
- IBRX 2.4B
- IPO Year
- PPBI 1997
- IBRX N/A
- Fundamental
- Price
- PPBI $24.85
- IBRX $2.66
- Analyst Decision
- PPBI Buy
- IBRX Buy
- Analyst Count
- PPBI 6
- IBRX 2
- Target Price
- PPBI $26.50
- IBRX $17.38
- AVG Volume (30 Days)
- PPBI 463.5K
- IBRX 5.9M
- Earning Date
- PPBI 01-27-2025
- IBRX 11-12-2024
- Dividend Yield
- PPBI 5.28%
- IBRX N/A
- EPS Growth
- PPBI N/A
- IBRX N/A
- EPS
- PPBI N/A
- IBRX N/A
- Revenue
- PPBI $379,785,000.00
- IBRX $7,332,000.00
- Revenue This Year
- PPBI N/A
- IBRX $2,572.99
- Revenue Next Year
- PPBI N/A
- IBRX $747.59
- P/E Ratio
- PPBI N/A
- IBRX N/A
- Revenue Growth
- PPBI N/A
- IBRX 1218.71
- 52 Week Low
- PPBI $20.52
- IBRX $2.61
- 52 Week High
- PPBI $30.28
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- PPBI 43.91
- IBRX 29.10
- Support Level
- PPBI $26.56
- IBRX $2.61
- Resistance Level
- PPBI $27.63
- IBRX $3.18
- Average True Range (ATR)
- PPBI 0.77
- IBRX 0.29
- MACD
- PPBI -0.21
- IBRX -0.22
- Stochastic Oscillator
- PPBI 9.12
- IBRX 3.58
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.